AbbVie Stock Prediction 2025, Best or Good?

Abbvie Stock Prediction 2025: Abbvie Inc. is a global pharmaceutical company headquartered in North Chicago, United States. The company achieved position 6 on the list of largest biomedical companies by revenue. From 2013 to 2024, Abbvie grew significantly with its focused innovation and commercial scale.  

Abbvie Inc. has been bringing differentiated healthcare products to the global market that benefit patients, customers, and healthcare providers.

The company has 75+ healthcare products, including the primary product Humira (adalimumab), which is administered via injection. In 2025, the USA FDA approved the company’s Parkinson’s disease treatment. Abbvie is fully approved to treat autoimmune diseases, including rheumatoid arthritis, Crohn’s disease, plaque psoriasis, and ulcerative colitis. 

Presently, Abbvie Inc.’s market cap is $359.5B. 

AbbVie Share Price is $169.63🔻On 14 Nov

AbbVie Share price (Last Traded Price) was $169.63 on 14 November. Its P/E ratio is 54.93. AbbVie’s earnings per share (EPS) is $3.65. AbbVie’s Dividend yield is 3.09%.

Key Events for AbbVie Stock Prediction 2025

Current Stocks Performance and Market Positions 2024

Abbvie stock is traded between  $199 and $203. Its market capitalization is $359.5B. Its latest P/E Ratio is 55.12. The Dividend Yield is 3.08%. The annual dividend value is $6.20 per share. The dividend P/E ratio is 54.6.

Abbvie stock’s 52-week Low price is $135.85 and its 52-week high is $207.32.

Abbvie Stocks Returns:

• 3.92% in 1 Month
• 7.32% in 3 Months
• 41.53% in 1 Year
• 145.34% in 5 Years.
• 507% Maximum.

Factors Influencing Abbvie Stock Prediction 2025

• Abbvie’s Quarter 3 report is stronger than the previous one. It indicates a potential hike in stock price. Though the Q3 earnings showed a massive revenue growth, earnings per share (EPS) missed estimates significantly. 
• Argus has set a new price target of $220 by the end of the current year. This target is driven by the strong sales growth of its product ‘Skyrizi, and ‘Ronivoq’. These 2 have replaced ‘Humira’ as key growth drivers.
• Skyrizi’s Q3 sales have surged from 52% to $3.21B. On the other hand, Rainboq’s sales increased from 47% to $1.61B. 
• Along with the strong Q3 results, Abbvie’s margins have stabilized. It contributes to its positive growth across AbbVie’s Neuroscience and Aesthetics portfolios.
• The stock has outperformed the S&P 500 index in the recent past. It indicates positive earnings expectations for the current and upcoming fiscal years. So, Deutsche Bank had set an increase price target of $180 (touched).
• Guggenheim Analyst Vamil Divan has raised Abbvie’s stock price prediction for 2025. The new price target is $221 at the beginning of 2025. 
• 65% buy ratings 34% hold ratings, and no sell ratings are seen based on 35 Wall Street analysts offering stock ratings Abbvie Inc.

Abbvie Stock Prediction 2025 

You May Also Like:
👉NVIDIA Stock Price Prediction 2030
👉Top 50 Dividend Aristocrats & 10 Bonus stocks & ETF
👉Tesla Stock Prediction 2025-2030 calculator

According to the given graph, the Yearly growth rate is nearly 41.17%. Here is an analysis and projection of AbbVie Inc.’s stock price target growth from January to December 2025

Current Growth Rate: AbbVie Stock Prediction 2025

• Over the past year, AbbVie Inc.’s Shares have shown approximately 41.17% growth rate. 
• AbbVie’s per share price was $142.03 on 8 November 2023. And On 8 November 2024, it is $200.51. (+41.17%)
• Given a one-year target of $210.00 in NASDAQ, we’ll project the monthly growth rate for 2025 based on this rate.
• Given a starting price of $210 in December 2024, we prepared our analysis

Projecting Forwrd Using 41.17% Annual growth:

• Assuming the stock continues to grow at an annual rate of 41.17%, this corresponds to an approximate monthly growth rate of 2.87% average.
• Using this monthly rate, we can estimate AbbVie’s stock price month-by-month for 2025

Month-by-Month AbbVie Stock Prediction 2025

Month	Projected Price
January 2025	$215.98
February 2025	$222.17
March 2025	$228.58
April 2025	$235.20
May 2025	$242.04
June 2025	$249.11
July 2025	$256.40
August 2025	$263.92
September 2025	$271.68
October 2025	$279.68
November 2025	$287.92
December 2025	$296.41

Detailed Calculation:
Starting from $210 in December 2024, each month’s price is calculated by multiplying the previous month’s price by 1.0287 (to account for the 2.87% monthly growth rate).
The projection gives a December 2025 estimated price of $296.41, assuming consistent growth.

AbbVie Inc.’s Stock Price Growth for January to December 2025 analysis:

1] Current Growth Rate:

• The stock has grown 41.17% over the last year, from around $142 (approximate starting price) to the last tarded price of $200.51.

2] Projecting Froward Using 41.17% Growth:

• If we assume a similar annual growth rate, the price could reach around $297 by the end of 2025 (using compound growth).

3] Detailed Calculation:

• If the stock grows 41.17% per year, then starting from $200.51 in December 2024: January 2025 to December 2025 (one full year): 215.98 × (1+0.4117)=296.41. 

4] Caveats: 

• This projection assumes the growth rate remains constant, which can vary due to market conditions, company performance, and broader economic factors.
• Analysts’ target price of $210 for December 2024, as previously mentioned, indicates a more conservative growth expectation, so this higher rate may be optimistic.

Final Talks: AbbVie Stock Prediction 2025

US-based healthcare sector stock AbbVie is an emerging company. Abbvie reached from $33 to $200.51 in 12 years. In this AbbVie Stock Prediction 2025 analysis, we projected the company’s price prediction month-by-month in 2025. If the stock reaches the most predicted $210 in December 2025, it will reach $296 in December 2025. We hope you liked the post ‘AbbVie Stock Prediction 2025. Let us know in the comment below.